Soligenix (SNGX) Projected to Release Earnings on Friday

Soligenix (NASDAQ:SNGX) is expected to announce its Q3 2026 resultson Friday, November 6th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. On average, analysts expect Soligenix to post ($0.55) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.

Soligenix Trading Down 1.5%

Shares of SNGX stock opened at $0.35 on Thursday. The stock has a market capitalization of $5.20 million, a price-to-earnings ratio of -0.36 and a beta of 2.04. Soligenix has a 12-month low of $0.28 and a 12-month high of $1.70. The stock’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.68.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Soligenix currently has an average rating of “Sell”.

Soligenix Company Profile

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.